BioCentury | Mar 26, 2020
Finance

March 25 Quick Takes: Temasek leads Abbisko’s $70M C round; plus IASO and Regenacy

Abbisko raises $70M series C  Abbisko Therapeutics Co. Ltd. raised $70 million in a series C round, bringing the total funds raised by the cancer company to $140 million since its founding in 2016. Temasek...
BC Extra | Oct 16, 2019
Financial News

China-heavy syndicate backs $80M series B for antiviral play Ansun

Ansun’s latest venture raise is in keeping with the San Diego-based antiviral company’s long-term strategy to add Chinese investors to help it penetrate the China market. Oceanpine Capital led Ansun BioPharma Inc.’s $80 million series...
BC Extra | Aug 10, 2019
Financial News

Aug. 9 Financial Quick Takes: Ironwood, Clovis, MeiraGTx, Dynavax, Biocytogen and more

Ironwood, Clovis price note deals  Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) raised $350 million in a convertible notes offering, including $175 million in 0.75% notes maturing in June 2024 and $175 million in 1.5% notes maturing June...
BioCentury | Jun 5, 2019
Finance

EpimAb raises $74M series B round to accelerate bispecific immuno-oncology pipeline expansion

With proof in hand that EpimAb can quickly move bispecific mAbs from concept to the clinic, the Shanghai company intends to use its $74 million series B round to rapidly expand its pipeline of bispecific...
BC Innovations | Feb 21, 2019
Emerging Company Profile

Refuge: Receptive CAR checkpoints

Refuge Biotechnologies Inc. aims to make CAR T cells more potent by suppressing their checkpoint genes and is using a form of CRISPR that knocks the genes down instead of out to improve safety. CEO...
BC Week In Review | Aug 10, 2018
Financial News

Apexigen announces $73M in series B, C rounds

Immuno-oncology company Apexigen Inc. (San Carlos, Calif.) raised a total of $73 million on Aug. 8 in its series B and C rounds. The company closed its series B round with $15 million led by...
BC Extra | Aug 8, 2018
Financial News

Apexigen announces $73M in series B, C rounds

Immuno-oncology company Apexigen Inc. (San Carlos, Calif.) raised a total of $73 million in its series B and C rounds. The company closed its series B round with $15 million led by Decheng Capital, while...
BioCentury | May 18, 2018
Finance

Ansun’s China ambitions

The China-heavy syndicate behind Ansun BioPharma Inc.’s $85 million series A round reflects the San Diego-based antiviral company’s long-term plans to penetrate the China market. Sinopharm Healthcare Fund and Lilly Asia Ventures led the round,...
BC Week In Review | May 18, 2018
Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

Ansun BioPharma Inc. (San Diego, Calif.) raised on May 14 a $85 million series A round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China,...
BC Extra | May 14, 2018
Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

Ansun BioPharma Inc. (San Diego, Calif.) raised a $85 million series A round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital,...
Items per page:
1 - 10 of 19
BioCentury | Mar 26, 2020
Finance

March 25 Quick Takes: Temasek leads Abbisko’s $70M C round; plus IASO and Regenacy

Abbisko raises $70M series C  Abbisko Therapeutics Co. Ltd. raised $70 million in a series C round, bringing the total funds raised by the cancer company to $140 million since its founding in 2016. Temasek...
BC Extra | Oct 16, 2019
Financial News

China-heavy syndicate backs $80M series B for antiviral play Ansun

Ansun’s latest venture raise is in keeping with the San Diego-based antiviral company’s long-term strategy to add Chinese investors to help it penetrate the China market. Oceanpine Capital led Ansun BioPharma Inc.’s $80 million series...
BC Extra | Aug 10, 2019
Financial News

Aug. 9 Financial Quick Takes: Ironwood, Clovis, MeiraGTx, Dynavax, Biocytogen and more

Ironwood, Clovis price note deals  Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) raised $350 million in a convertible notes offering, including $175 million in 0.75% notes maturing in June 2024 and $175 million in 1.5% notes maturing June...
BioCentury | Jun 5, 2019
Finance

EpimAb raises $74M series B round to accelerate bispecific immuno-oncology pipeline expansion

With proof in hand that EpimAb can quickly move bispecific mAbs from concept to the clinic, the Shanghai company intends to use its $74 million series B round to rapidly expand its pipeline of bispecific...
BC Innovations | Feb 21, 2019
Emerging Company Profile

Refuge: Receptive CAR checkpoints

Refuge Biotechnologies Inc. aims to make CAR T cells more potent by suppressing their checkpoint genes and is using a form of CRISPR that knocks the genes down instead of out to improve safety. CEO...
BC Week In Review | Aug 10, 2018
Financial News

Apexigen announces $73M in series B, C rounds

Immuno-oncology company Apexigen Inc. (San Carlos, Calif.) raised a total of $73 million on Aug. 8 in its series B and C rounds. The company closed its series B round with $15 million led by...
BC Extra | Aug 8, 2018
Financial News

Apexigen announces $73M in series B, C rounds

Immuno-oncology company Apexigen Inc. (San Carlos, Calif.) raised a total of $73 million in its series B and C rounds. The company closed its series B round with $15 million led by Decheng Capital, while...
BioCentury | May 18, 2018
Finance

Ansun’s China ambitions

The China-heavy syndicate behind Ansun BioPharma Inc.’s $85 million series A round reflects the San Diego-based antiviral company’s long-term plans to penetrate the China market. Sinopharm Healthcare Fund and Lilly Asia Ventures led the round,...
BC Week In Review | May 18, 2018
Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

Ansun BioPharma Inc. (San Diego, Calif.) raised on May 14 a $85 million series A round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China,...
BC Extra | May 14, 2018
Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

Ansun BioPharma Inc. (San Diego, Calif.) raised a $85 million series A round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital,...
Items per page:
1 - 10 of 19